A comparative study on the utility of biomarkers – serum interleukin-13 against serum immunoglobulin E in assessing the severity of asthma

Authors

  • Prasanna Raju Department of Paediatrics, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamilnadu, India https://orcid.org/0000-0002-4161-5904
  • Subash Sundar Department of Paediatrics, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamilnadu, India https://orcid.org/0000-0002-6255-7125
  • Preethi Suresh Department of Paediatrics, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamilnadu, India https://orcid.org/0009-0005-6373-6386
  • Jayaprakash Thulukanam Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamilnadu, India https://orcid.org/0000-0003-1647-174X
  • Padmanaban Srinivasan Department of Statistics, NIRT, Indian Council of Medical Research, Chennai, India https://orcid.org/0000-0002-1633-5193

DOI:

https://doi.org/10.15584/ejcem.2025.2.27

Keywords:

serum IgE, serum IL-13, severity of asthma

Abstract

Introduction and aim. Asthma is a complex respiratory condition with fluctuating symptoms, airflow obstruction, bronchial hyperresponsiveness, and inflammation. Interleukin (IL)-13 induces various biological responses, including B-cell immunoglobulin E (IgE), eosinophil chemo-attractants, and mucus-secreting goblet cell maturation. B-cell immunoglobulin E antibodies are essential for the onset and propagation of the inflammatory cascade, triggering the allergic response. The aim was to compare the utility of biomarkers – serum IL-13 against serum IgE in assessing the severity of asthma.


Material and methods. A cross-sectional observational study was conducted involving 68 asthmatic children aged 6–12 years and 68 age- and sex-matched healthy controls. Asthma severity was assessed using spirometry and categorized as mild, moderate, or severe based on GINA guidelines. Serum IL-13 and IgE levels were measured using validated using enzyme-linked immunosorbent assay.


Results. The study confirmed elevated levels of serum IL-13 and IgE in children with asthma compared to the control group, suggesting their involvement in the development of asthma (p<0.001). The threshold values for identifying the existence of asthma were 1.86 pg/mL for IL-13 and 314 ng/ml for IgE. The IL-13 level could accurately classify asthmatic children as having either moderate or severe asthma, using a cut-off value of ≥2.66 pg/mL, with a statistically significant p=0.001. However, no such results were observed with IgE.


Conclusion. Bronchial asthma patients had markedly higher levels of total IgE and IL-13 compared to the healthy controls included in the study. Furthermore, it has been shown that IL-13 plays a role in discerning the extent of asthma severity.

Downloads

Download data is not yet available.

References

National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2007 Aug. Section 2, Definition, Pathophysiology and Pathogenesis of Asthma, and Natural History of Asthma. https://www.ncbi.nlm.nih.gov/books/NBK7223. Accessed November 20, 2024.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. www.ginaasthma.org. Accessed January 20, 2022.

Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:246. doi: 10.3389/fped.2019.00246

Tai A, Tran H, Roberts M, et al. Outcomes of childhood asthma to the age of 50 years. J Allergy Clin Immunol. 2014;133(6):1572-1578.e3. doi: 10.1016/j.jaci.2013.12.1033

Nair P, O’Byrne PM. The interleukin-13 paradox in asthma: effective biology, ineffective biologicals. Eur Respir J. 2019;53(2):1802250. doi: 10.1183/13993003.02250-2018

Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med. 2005;11(1):27-34. doi: 10.1097/01.mcp.0000147860.83639.30

Peng Z. Vaccines targeting IgE in the treatment of asthma and allergy. Human Vaccines. 2009;5(5):302-309. doi: 10.4161/hv.5.5.744

Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130(3):647-654.e10. doi: 10.1016/j.jaci.2012.06.025

Sherrill DL, Lebowitz MD, Halonen M, Barbee RA, Burrows B. Longitudinal evaluation of the association between pulmonary function and total serum IgE. Am J Respir Crit Care Med. 1995;152(1):98-102. doi: 10.1164/ajrccm.152.1.7599870

Van Der Pouw Kraan TCTM, Van Der Zee JS, Boeije LCM, De Groot ER, Stapel SO, Aarden LA. The role of IL-13 in IgE synthesis by allergic asthma patients. Clin Exp Immunol. 1998;111(1):129-135. doi: 10.1046/j.1365-2249.1998.00471.x

National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma.; 2007. https://www.nhlbi.nih.gov/sites/default/files/media/docs/EPR-3_Asthma_Full_Report_2007.pdf. Accessed January 20, 2022.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention.; 2019. https://ginasthma. org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed January 20, 2022.

Spahn JD, Cherniack R, Paull K, Gelfand EW. Is forced expiratory volume in one second the best measure of severity in childhood asthma? Am J Respir Crit Care Med. 2004;169(7):784-786. doi: 10.1164/rccm.200309-1234oe

Janeva EJ, Goseva Z, Gjorchev A, et al. The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13 and FEV1. Open Access Macedonian Journal of Medical Sciences. 2015;3(2):268-272. doi: 10.3889/oamjms.2015.053

Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202:175-190. doi:10.1111/j.0105-2896.2004.00215.x

Nair P, O’Byrne PM. The interleukin-13 paradox in asthma: effective biology, ineffective biologicals. Eur Respir J. 2019;53(2):1802250. doi: 10.1183/13993003.022502018

Humbert M, Durham S, Kimmitt P, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol. 1997;99(5):657-665. doi: 10.1016/s0091-6749(97)70028-9

Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121(3):685-691. doi: 10.1016/j.jaci.2008.01.005

Javaid K, Nadeem A, Adhami SUZ, et al. Positive correlation of serum interleukin-13 and total immunoglobulin E in bronchial asthma patients. Bangladesh Journal of Medical Science. 2022;21(3):596-600. doi: 10.3329/bjms.v21i3.59573

Jebur MS, Saud AM. Serum levels of total IGE and interleukin-13 in a sample of allergic asthma patients in Baghdad. Iraqi Journal of Science. 2020:3208-3214. doi: 10.24996/ijs.2020.61.12.8

Davila I, Valero A, Entrenas LM, Valveny N, Herráez L; SIGE Study Group. Relationship between serum total IgE and disease severity in patients with allergic asthma in Spain. J Investig Allergol Clin Immunol. 2015;25(2):120-127.

Sandeep T, Roopakala MS, Silvia CR, Chandrashekara S, Rao M. Evaluation of serum immunoglobulin E levels in bronchial asthma. Lung India. 2010;27(3):138-140. doi: 10.4103/0970-2113.68312.

Rathoria E, Bansal U, Gupta A, Gupta NB, Ahuja R, Rathoria R. Study of serum IgE levels in childhood asthma in Barabanki region, India. International Journal of Contemporary Pediatrics. 2018;5(5):1755. doi:10.18203/23493291.ijcp20183369

Raju P, Sundar S, Suresh P, Vajravelu LK, Aravindhan V. Interleukin-13 as a potential biomarker in the management of pediatric asthma – a longitudinal study. Eur J Clin Exp Med. 2025;23(1):15-20. doi: 10.15584/ejcem.2025.1.3

Makieieva N, Malakhova V, Vasylchenko Y, Tsymbal V. Are Level of IL-13 and IL-4 Predictive for Formation of Chronic Inflammation in Children with Asthma? Adv Respir Med. 2020;88(4):320-326. doi: 10.5603/arm.a2020.0108

Khattab M, Hussein M, Khater W. IL 13rs20541 Single Nucleotide Polymorphism and Serum IL -13 Level in Children with Bronchial Asthma. The Egyptian Journal of Pediatric Allergy and Immunology. 2023;21(1):27-33. doi: 10.21608/ejpa.2023.170190.1045

Downloads

Published

2025-06-30

How to Cite

Raju, P., Sundar, S., Suresh, P., Thulukanam, J., & Srinivasan, P. (2025). A comparative study on the utility of biomarkers – serum interleukin-13 against serum immunoglobulin E in assessing the severity of asthma. European Journal of Clinical and Experimental Medicine, 23(2), 445–452. https://doi.org/10.15584/ejcem.2025.2.27

Issue

Vol. 23 No. 2 (2025)

Section

ORIGINAL PAPERS

License

Copyright (c) 2025 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.